| 
					
						|  |  |  
						|  |  
						|  |  
	
		| 
				
					|  | 
							
								|  |  
								|  | 
										
											| Trade Leads |  
											|  |  
											| 
													
														| Sell Semaglutide
 | 
																
																	| [Sell] Sell Semaglutide |  
																	| Subject:  Sell Semaglutide |  
																	| Effective Period:  1 month |  
																	| Date-Time:  2018/11/15 14:34:08 |  |  
														|  |  
														| Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-¦Ã-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
 CAS NO.: 910463-68-2
 Molecular Formula: C187H291N45O59
 Molecular Weight: 4,113.64
 Appearance:White Crystalline Powder
 Purity: 99.38%
 Identification: Infrared Absorption
 Loss On Drying: ¡Ü0.2%
 Residue On Ignition: ¡Ü0.3%
 Chloride:¡Ü0.05%
 Sulfate:¡Ü0.03%
 Heavy Metals:¡Ü0.0015%
 Application:
 1. Used as both injection-type or oral-type drug.
 2. Used for the treatment of obesity.
 3. Improve cardiovascular function
 4. Treatment of type 2 diabetes in adults
 About Semaglutide:
 Semaglutide(Ozempic) is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.Semaglutide is a pharmaceutical drug which is used for the treatment of type 2 diabetes. Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. Semaglutide(Ozempic), a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM).
 In humans semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1).
 Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist.
 Furthermore, semaglutide demonstrated a significant, beneficial effect on cardiovascular outcomes and a safety profile similar to that of other GLP-1 receptor agonists.Semaglutide also improves cardiovascular function, reduces the risk of stroke by 39%, and reduces the risk of myocardial infarction by 26%.
 |  |  
											|  |  
											| 
  
    | Contact Information |  
    | Company Name: | Green Heaven Pvt. Ltd. |  
    | Contact Person: | Mr. Mohamed Atia |  
    | Address: | Green Heaven India,14 Block,Hingna MIDC,Maharashtra,India. |  
    | Zip: | 440028 |  
    | Telephone: |  |  
    | Fax: |  
    | E-mail: |  
    | Web Site: |  |  |  |  |  |  
		|  |  |